NCT03588091 2025-08-22Neoadjuvant Study of Pyrotinib in Combination With Trastuzumab in Patients With HER2 Positive Breast CancerJiangsu HengRui Medicine Co., Ltd.Phase 3 Completed355 enrolled
NCT07115095 2025-08-11Tumor Markers for Efficacy of Dual-Target Therapy in HER2+ Breast CancerShaanxi Provincial Cancer HospitalPhase NA Completed98 enrolled
NCT06833268 2025-07-08Real-world Outcomes of Patients With HER2+ Metastatic Breast Cancer After Treatment With Trastuzumab DeruxtecanDaiichi SankyoCompleted228 enrolled